nodes	percent_of_prediction	percent_of_DWPC	metapath
Formoterol—CYP2A6—Methoxsalen—psoriasis	0.165	0.264	CbGbCtD
Formoterol—CYP2A6—Prednisolone—psoriasis	0.0802	0.128	CbGbCtD
Formoterol—CYP2D6—Hydroxyurea—psoriasis	0.0567	0.0907	CbGbCtD
Formoterol—CYP2A6—Dexamethasone—psoriasis	0.0473	0.0756	CbGbCtD
Formoterol—CYP2C19—Cholecalciferol—psoriasis	0.0452	0.0723	CbGbCtD
Formoterol—CYP2C9—Cholecalciferol—psoriasis	0.0376	0.0601	CbGbCtD
Formoterol—CYP2D6—Cholecalciferol—psoriasis	0.0344	0.055	CbGbCtD
Formoterol—CYP2C19—Prednisone—psoriasis	0.0313	0.0501	CbGbCtD
Formoterol—CYP2C19—Cyclosporine—psoriasis	0.0297	0.0475	CbGbCtD
Formoterol—CYP2C9—Cyclosporine—psoriasis	0.0247	0.0395	CbGbCtD
Formoterol—CYP2D6—Cyclosporine—psoriasis	0.0226	0.0361	CbGbCtD
Formoterol—CYP2C19—Dexamethasone—psoriasis	0.0196	0.0313	CbGbCtD
Formoterol—CYP2C9—Dexamethasone—psoriasis	0.0163	0.026	CbGbCtD
Formoterol—CYP2D6—Dexamethasone—psoriasis	0.0149	0.0238	CbGbCtD
Formoterol—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.00266	0.102	CbGpPWpGaD
Formoterol—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.00165	0.063	CbGpPWpGaD
Formoterol—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00162	0.0619	CbGpPWpGaD
Formoterol—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00149	0.057	CbGpPWpGaD
Formoterol—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00148	0.0565	CbGpPWpGaD
Formoterol—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00139	0.0531	CbGpPWpGaD
Formoterol—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00101	0.0384	CbGpPWpGaD
Formoterol—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000925	0.0353	CbGpPWpGaD
Formoterol—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000917	0.035	CbGpPWpGaD
Formoterol—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000685	0.0261	CbGpPWpGaD
Formoterol—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000676	0.0258	CbGpPWpGaD
Formoterol—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000555	0.0212	CbGpPWpGaD
Formoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000429	0.0164	CbGpPWpGaD
Formoterol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000418	0.0159	CbGpPWpGaD
Formoterol—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000412	0.0157	CbGpPWpGaD
Formoterol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000384	0.0147	CbGpPWpGaD
Formoterol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000381	0.0145	CbGpPWpGaD
Formoterol—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000379	0.0145	CbGpPWpGaD
Formoterol—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000376	0.0143	CbGpPWpGaD
Formoterol—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000339	0.0129	CbGpPWpGaD
Formoterol—ADRB1—Melatonin metabolism and effects—APOE—psoriasis	0.000327	0.0125	CbGpPWpGaD
Formoterol—ADRB1—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000317	0.0121	CbGpPWpGaD
Formoterol—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000311	0.0119	CbGpPWpGaD
Formoterol—ADRB2—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000311	0.0118	CbGpPWpGaD
Formoterol—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000309	0.0118	CbGpPWpGaD
Formoterol—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000295	0.0113	CbGpPWpGaD
Formoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000284	0.0109	CbGpPWpGaD
Formoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000274	0.0104	CbGpPWpGaD
Formoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000248	0.00948	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000231	0.00883	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000226	0.00863	CbGpPWpGaD
Formoterol—ADRB1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000195	0.00743	CbGpPWpGaD
Formoterol—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.00018	0.00686	CbGpPWpGaD
Formoterol—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000177	0.00677	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—HCAR2—psoriasis	0.000176	0.00672	CbGpPWpGaD
Formoterol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000175	0.00668	CbGpPWpGaD
Formoterol—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000174	0.00665	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—HCAR2—psoriasis	0.000172	0.00657	CbGpPWpGaD
Formoterol—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000165	0.00631	CbGpPWpGaD
Formoterol—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000164	0.00627	CbGpPWpGaD
Formoterol—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000164	0.00626	CbGpPWpGaD
Formoterol—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000163	0.00623	CbGpPWpGaD
Formoterol—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000162	0.00617	CbGpPWpGaD
Formoterol—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.00016	0.00612	CbGpPWpGaD
Formoterol—Constipation—Cyclosporine—psoriasis	0.000135	0.000389	CcSEcCtD
Formoterol—Pain—Cyclosporine—psoriasis	0.000135	0.000389	CcSEcCtD
Formoterol—Dry mouth—Triamcinolone—psoriasis	0.000135	0.000388	CcSEcCtD
Formoterol—Angioedema—Betamethasone—psoriasis	0.000135	0.000387	CcSEcCtD
Formoterol—Angioedema—Dexamethasone—psoriasis	0.000135	0.000387	CcSEcCtD
Formoterol—Diarrhoea—Mycophenolic acid—psoriasis	0.000134	0.000385	CcSEcCtD
Formoterol—Conjunctivitis—Methotrexate—psoriasis	0.000133	0.000383	CcSEcCtD
Formoterol—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000133	0.000383	CcSEcCtD
Formoterol—Immune system disorder—Prednisone—psoriasis	0.000133	0.000382	CcSEcCtD
Formoterol—Malaise—Dexamethasone—psoriasis	0.000133	0.000382	CcSEcCtD
Formoterol—Malaise—Betamethasone—psoriasis	0.000133	0.000382	CcSEcCtD
Formoterol—Oedema—Triamcinolone—psoriasis	0.000133	0.000381	CcSEcCtD
Formoterol—Anaphylactic shock—Triamcinolone—psoriasis	0.000133	0.000381	CcSEcCtD
Formoterol—Pain—Mycophenolate mofetil—psoriasis	0.000132	0.00038	CcSEcCtD
Formoterol—Constipation—Mycophenolate mofetil—psoriasis	0.000132	0.00038	CcSEcCtD
Formoterol—Arrhythmia—Prednisone—psoriasis	0.000132	0.000378	CcSEcCtD
Formoterol—Infection—Triamcinolone—psoriasis	0.000132	0.000378	CcSEcCtD
Formoterol—Hypotension—Hydrocortisone—psoriasis	0.000132	0.000378	CcSEcCtD
Formoterol—Haematuria—Methotrexate—psoriasis	0.000131	0.000376	CcSEcCtD
Formoterol—Feeling abnormal—Cyclosporine—psoriasis	0.000131	0.000375	CcSEcCtD
Formoterol—Insomnia—Prednisolone—psoriasis	0.00013	0.000374	CcSEcCtD
Formoterol—Gastrointestinal pain—Cyclosporine—psoriasis	0.00013	0.000372	CcSEcCtD
Formoterol—Dizziness—Mycophenolic acid—psoriasis	0.00013	0.000372	CcSEcCtD
Formoterol—Tachycardia—Triamcinolone—psoriasis	0.000129	0.000372	CcSEcCtD
Formoterol—Mental disorder—Prednisone—psoriasis	0.000129	0.000371	CcSEcCtD
Formoterol—Malnutrition—Prednisone—psoriasis	0.000128	0.000369	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000128	0.000368	CcSEcCtD
Formoterol—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000127	0.000366	CcSEcCtD
Formoterol—Insomnia—Hydrocortisone—psoriasis	0.000127	0.000366	CcSEcCtD
Formoterol—Hypertension—Betamethasone—psoriasis	0.000127	0.000365	CcSEcCtD
Formoterol—Hypertension—Dexamethasone—psoriasis	0.000127	0.000365	CcSEcCtD
Formoterol—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000126	0.000363	CcSEcCtD
Formoterol—Urticaria—Cyclosporine—psoriasis	0.000126	0.000361	CcSEcCtD
Formoterol—Myalgia—Betamethasone—psoriasis	0.000125	0.00036	CcSEcCtD
Formoterol—Myalgia—Dexamethasone—psoriasis	0.000125	0.00036	CcSEcCtD
Formoterol—Abdominal pain—Cyclosporine—psoriasis	0.000125	0.00036	CcSEcCtD
Formoterol—Body temperature increased—Cyclosporine—psoriasis	0.000125	0.00036	CcSEcCtD
Formoterol—Anxiety—Dexamethasone—psoriasis	0.000125	0.000359	CcSEcCtD
Formoterol—Anxiety—Betamethasone—psoriasis	0.000125	0.000359	CcSEcCtD
Formoterol—Vomiting—Mycophenolic acid—psoriasis	0.000125	0.000358	CcSEcCtD
Formoterol—Discomfort—Betamethasone—psoriasis	0.000124	0.000356	CcSEcCtD
Formoterol—Discomfort—Dexamethasone—psoriasis	0.000124	0.000356	CcSEcCtD
Formoterol—Dyspepsia—Hydrocortisone—psoriasis	0.000124	0.000356	CcSEcCtD
Formoterol—Rash—Mycophenolic acid—psoriasis	0.000123	0.000355	CcSEcCtD
Formoterol—Dermatitis—Mycophenolic acid—psoriasis	0.000123	0.000354	CcSEcCtD
Formoterol—Pain—Prednisolone—psoriasis	0.000123	0.000354	CcSEcCtD
Formoterol—Urticaria—Mycophenolate mofetil—psoriasis	0.000123	0.000353	CcSEcCtD
Formoterol—Headache—Mycophenolic acid—psoriasis	0.000123	0.000352	CcSEcCtD
Formoterol—Pharyngitis—Methotrexate—psoriasis	0.000122	0.000351	CcSEcCtD
Formoterol—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000122	0.000351	CcSEcCtD
Formoterol—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000122	0.000351	CcSEcCtD
Formoterol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000122	0.00465	CbGpPWpGaD
Formoterol—Urinary tract disorder—Methotrexate—psoriasis	0.000122	0.000349	CcSEcCtD
Formoterol—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000122	0.000349	CcSEcCtD
Formoterol—Fatigue—Hydrocortisone—psoriasis	0.000121	0.000349	CcSEcCtD
Formoterol—Urethral disorder—Methotrexate—psoriasis	0.000121	0.000347	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000121	0.000347	CcSEcCtD
Formoterol—Pain—Hydrocortisone—psoriasis	0.00012	0.000346	CcSEcCtD
Formoterol—Anaphylactic shock—Dexamethasone—psoriasis	0.00012	0.000345	CcSEcCtD
Formoterol—Anaphylactic shock—Betamethasone—psoriasis	0.00012	0.000345	CcSEcCtD
Formoterol—Oedema—Dexamethasone—psoriasis	0.00012	0.000345	CcSEcCtD
Formoterol—Oedema—Betamethasone—psoriasis	0.00012	0.000345	CcSEcCtD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00012	0.00458	CbGpPWpGaD
Formoterol—Insomnia—Triamcinolone—psoriasis	0.00012	0.000344	CcSEcCtD
Formoterol—Infection—Betamethasone—psoriasis	0.00012	0.000343	CcSEcCtD
Formoterol—Infection—Dexamethasone—psoriasis	0.00012	0.000343	CcSEcCtD
Formoterol—Ill-defined disorder—Prednisone—psoriasis	0.000119	0.000342	CcSEcCtD
Formoterol—Feeling abnormal—Prednisolone—psoriasis	0.000119	0.000341	CcSEcCtD
Formoterol—Visual impairment—Methotrexate—psoriasis	0.000119	0.000341	CcSEcCtD
Formoterol—Dyspnoea—Triamcinolone—psoriasis	0.000118	0.000339	CcSEcCtD
Formoterol—Nervous system disorder—Dexamethasone—psoriasis	0.000118	0.000339	CcSEcCtD
Formoterol—Nervous system disorder—Betamethasone—psoriasis	0.000118	0.000339	CcSEcCtD
Formoterol—Agitation—Prednisone—psoriasis	0.000118	0.000339	CcSEcCtD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000118	0.00448	CbGpPWpGaD
Formoterol—Tachycardia—Betamethasone—psoriasis	0.000117	0.000337	CcSEcCtD
Formoterol—Tachycardia—Dexamethasone—psoriasis	0.000117	0.000337	CcSEcCtD
Formoterol—Angioedema—Prednisone—psoriasis	0.000117	0.000337	CcSEcCtD
Formoterol—Hypersensitivity—Cyclosporine—psoriasis	0.000117	0.000335	CcSEcCtD
Formoterol—Dyspepsia—Triamcinolone—psoriasis	0.000117	0.000335	CcSEcCtD
Formoterol—Nausea—Mycophenolic acid—psoriasis	0.000116	0.000334	CcSEcCtD
Formoterol—Feeling abnormal—Hydrocortisone—psoriasis	0.000116	0.000333	CcSEcCtD
Formoterol—Malaise—Prednisone—psoriasis	0.000116	0.000332	CcSEcCtD
Formoterol—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000115	0.000331	CcSEcCtD
Formoterol—Urticaria—Prednisolone—psoriasis	0.000115	0.000329	CcSEcCtD
Formoterol—Cardiac disorder—Methotrexate—psoriasis	0.000114	0.000328	CcSEcCtD
Formoterol—Fatigue—Triamcinolone—psoriasis	0.000114	0.000328	CcSEcCtD
Formoterol—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000114	0.000327	CcSEcCtD
Formoterol—Asthenia—Cyclosporine—psoriasis	0.000114	0.000326	CcSEcCtD
Formoterol—Pain—Triamcinolone—psoriasis	0.000113	0.000326	CcSEcCtD
Formoterol—Hypotension—Betamethasone—psoriasis	0.000112	0.000323	CcSEcCtD
Formoterol—Hypotension—Dexamethasone—psoriasis	0.000112	0.000323	CcSEcCtD
Formoterol—Pruritus—Cyclosporine—psoriasis	0.000112	0.000322	CcSEcCtD
Formoterol—Urticaria—Hydrocortisone—psoriasis	0.000112	0.000321	CcSEcCtD
Formoterol—Immune system disorder—Methotrexate—psoriasis	0.000111	0.00032	CcSEcCtD
Formoterol—Body temperature increased—Hydrocortisone—psoriasis	0.000111	0.00032	CcSEcCtD
Formoterol—Abdominal pain—Hydrocortisone—psoriasis	0.000111	0.00032	CcSEcCtD
Formoterol—Mediastinal disorder—Methotrexate—psoriasis	0.000111	0.000319	CcSEcCtD
Formoterol—Asthenia—Mycophenolate mofetil—psoriasis	0.000111	0.000318	CcSEcCtD
Formoterol—Hypertension—Prednisone—psoriasis	0.000111	0.000318	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.00011	0.000315	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Betamethasone—psoriasis	0.00011	0.000315	CcSEcCtD
Formoterol—Pruritus—Mycophenolate mofetil—psoriasis	0.000109	0.000314	CcSEcCtD
Formoterol—Myalgia—Prednisone—psoriasis	0.000109	0.000314	CcSEcCtD
Formoterol—Arthralgia—Prednisone—psoriasis	0.000109	0.000314	CcSEcCtD
Formoterol—Feeling abnormal—Triamcinolone—psoriasis	0.000109	0.000314	CcSEcCtD
Formoterol—Anxiety—Prednisone—psoriasis	0.000109	0.000313	CcSEcCtD
Formoterol—Insomnia—Dexamethasone—psoriasis	0.000109	0.000312	CcSEcCtD
Formoterol—Insomnia—Betamethasone—psoriasis	0.000109	0.000312	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000109	0.000312	CcSEcCtD
Formoterol—Diarrhoea—Cyclosporine—psoriasis	0.000108	0.000311	CcSEcCtD
Formoterol—Discomfort—Prednisone—psoriasis	0.000108	0.00031	CcSEcCtD
Formoterol—Mental disorder—Methotrexate—psoriasis	0.000108	0.00031	CcSEcCtD
Formoterol—Malnutrition—Methotrexate—psoriasis	0.000107	0.000308	CcSEcCtD
Formoterol—Hypersensitivity—Prednisolone—psoriasis	0.000106	0.000305	CcSEcCtD
Formoterol—Dyspepsia—Dexamethasone—psoriasis	0.000106	0.000304	CcSEcCtD
Formoterol—Dyspepsia—Betamethasone—psoriasis	0.000106	0.000304	CcSEcCtD
Formoterol—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000106	0.000304	CcSEcCtD
Formoterol—Urticaria—Triamcinolone—psoriasis	0.000105	0.000302	CcSEcCtD
Formoterol—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	0.000105	0.00401	CbGpPWpGaD
Formoterol—Dysgeusia—Methotrexate—psoriasis	0.000105	0.000302	CcSEcCtD
Formoterol—Body temperature increased—Triamcinolone—psoriasis	0.000105	0.000301	CcSEcCtD
Formoterol—Dizziness—Cyclosporine—psoriasis	0.000105	0.000301	CcSEcCtD
Formoterol—Anaphylactic shock—Prednisone—psoriasis	0.000105	0.000301	CcSEcCtD
Formoterol—Oedema—Prednisone—psoriasis	0.000105	0.000301	CcSEcCtD
Formoterol—Infection—Prednisone—psoriasis	0.000104	0.000299	CcSEcCtD
Formoterol—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000104	0.000298	CcSEcCtD
Formoterol—Gastrointestinal disorder—Betamethasone—psoriasis	0.000104	0.000298	CcSEcCtD
Formoterol—Back pain—Methotrexate—psoriasis	0.000104	0.000298	CcSEcCtD
Formoterol—Hypersensitivity—Hydrocortisone—psoriasis	0.000104	0.000298	CcSEcCtD
Formoterol—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000104	0.00396	CbGpPWpGaD
Formoterol—Fatigue—Dexamethasone—psoriasis	0.000104	0.000298	CcSEcCtD
Formoterol—Fatigue—Betamethasone—psoriasis	0.000104	0.000298	CcSEcCtD
Formoterol—Pain—Dexamethasone—psoriasis	0.000103	0.000295	CcSEcCtD
Formoterol—Pain—Betamethasone—psoriasis	0.000103	0.000295	CcSEcCtD
Formoterol—Nervous system disorder—Prednisone—psoriasis	0.000103	0.000295	CcSEcCtD
Formoterol—Tachycardia—Prednisone—psoriasis	0.000102	0.000294	CcSEcCtD
Formoterol—Dizziness—Mycophenolate mofetil—psoriasis	0.000102	0.000293	CcSEcCtD
Formoterol—Skin disorder—Prednisone—psoriasis	0.000102	0.000292	CcSEcCtD
Formoterol—Asthenia—Hydrocortisone—psoriasis	0.000101	0.00029	CcSEcCtD
Formoterol—Vomiting—Cyclosporine—psoriasis	0.000101	0.000289	CcSEcCtD
Formoterol—Rash—Cyclosporine—psoriasis	9.99e-05	0.000287	CcSEcCtD
Formoterol—Dermatitis—Cyclosporine—psoriasis	9.98e-05	0.000287	CcSEcCtD
Formoterol—Pruritus—Hydrocortisone—psoriasis	9.96e-05	0.000286	CcSEcCtD
Formoterol—ADRB1—GPCR downstream signaling—HCAR2—psoriasis	9.96e-05	0.0038	CbGpPWpGaD
Formoterol—Ill-defined disorder—Methotrexate—psoriasis	9.95e-05	0.000286	CcSEcCtD
Formoterol—Headache—Cyclosporine—psoriasis	9.93e-05	0.000285	CcSEcCtD
Formoterol—Feeling abnormal—Dexamethasone—psoriasis	9.91e-05	0.000285	CcSEcCtD
Formoterol—Feeling abnormal—Betamethasone—psoriasis	9.91e-05	0.000285	CcSEcCtD
Formoterol—Gastrointestinal pain—Dexamethasone—psoriasis	9.84e-05	0.000282	CcSEcCtD
Formoterol—Gastrointestinal pain—Betamethasone—psoriasis	9.84e-05	0.000282	CcSEcCtD
Formoterol—Vomiting—Mycophenolate mofetil—psoriasis	9.83e-05	0.000282	CcSEcCtD
Formoterol—Hypersensitivity—Triamcinolone—psoriasis	9.77e-05	0.00028	CcSEcCtD
Formoterol—Rash—Mycophenolate mofetil—psoriasis	9.75e-05	0.00028	CcSEcCtD
Formoterol—ADRB2—GPCR downstream signaling—HCAR2—psoriasis	9.74e-05	0.00372	CbGpPWpGaD
Formoterol—Dermatitis—Mycophenolate mofetil—psoriasis	9.74e-05	0.00028	CcSEcCtD
Formoterol—Headache—Mycophenolate mofetil—psoriasis	9.68e-05	0.000278	CcSEcCtD
Formoterol—Malaise—Methotrexate—psoriasis	9.67e-05	0.000278	CcSEcCtD
Formoterol—Diarrhoea—Hydrocortisone—psoriasis	9.63e-05	0.000277	CcSEcCtD
Formoterol—Urticaria—Dexamethasone—psoriasis	9.56e-05	0.000274	CcSEcCtD
Formoterol—Urticaria—Betamethasone—psoriasis	9.56e-05	0.000274	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Prednisone—psoriasis	9.55e-05	0.000274	CcSEcCtD
Formoterol—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	9.54e-05	0.00364	CbGpPWpGaD
Formoterol—Dizziness—Prednisolone—psoriasis	9.53e-05	0.000274	CcSEcCtD
Formoterol—Asthenia—Triamcinolone—psoriasis	9.51e-05	0.000273	CcSEcCtD
Formoterol—Abdominal pain—Dexamethasone—psoriasis	9.51e-05	0.000273	CcSEcCtD
Formoterol—Body temperature increased—Dexamethasone—psoriasis	9.51e-05	0.000273	CcSEcCtD
Formoterol—Body temperature increased—Betamethasone—psoriasis	9.51e-05	0.000273	CcSEcCtD
Formoterol—Abdominal pain—Betamethasone—psoriasis	9.51e-05	0.000273	CcSEcCtD
Formoterol—Insomnia—Prednisone—psoriasis	9.48e-05	0.000272	CcSEcCtD
Formoterol—Nausea—Cyclosporine—psoriasis	9.41e-05	0.00027	CcSEcCtD
Formoterol—Pruritus—Triamcinolone—psoriasis	9.38e-05	0.000269	CcSEcCtD
Formoterol—Cough—Methotrexate—psoriasis	9.36e-05	0.000269	CcSEcCtD
Formoterol—Dizziness—Hydrocortisone—psoriasis	9.31e-05	0.000267	CcSEcCtD
Formoterol—Dyspepsia—Prednisone—psoriasis	9.22e-05	0.000265	CcSEcCtD
Formoterol—Nausea—Mycophenolate mofetil—psoriasis	9.18e-05	0.000264	CcSEcCtD
Formoterol—ADRB1—GPCR ligand binding—CCL20—psoriasis	9.15e-05	0.00349	CbGpPWpGaD
Formoterol—Arthralgia—Methotrexate—psoriasis	9.13e-05	0.000262	CcSEcCtD
Formoterol—Chest pain—Methotrexate—psoriasis	9.13e-05	0.000262	CcSEcCtD
Formoterol—Myalgia—Methotrexate—psoriasis	9.13e-05	0.000262	CcSEcCtD
Formoterol—Rash—Prednisolone—psoriasis	9.09e-05	0.000261	CcSEcCtD
Formoterol—Dermatitis—Prednisolone—psoriasis	9.08e-05	0.000261	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	9.07e-05	0.00026	CcSEcCtD
Formoterol—ADRB1—Signaling by GPCR—HCAR2—psoriasis	9.04e-05	0.00345	CbGpPWpGaD
Formoterol—Fatigue—Prednisone—psoriasis	9.03e-05	0.000259	CcSEcCtD
Formoterol—Headache—Prednisolone—psoriasis	9.03e-05	0.000259	CcSEcCtD
Formoterol—Discomfort—Methotrexate—psoriasis	9.02e-05	0.000259	CcSEcCtD
Formoterol—Constipation—Prednisone—psoriasis	8.96e-05	0.000257	CcSEcCtD
Formoterol—Vomiting—Hydrocortisone—psoriasis	8.95e-05	0.000257	CcSEcCtD
Formoterol—ADRB2—GPCR ligand binding—CCL20—psoriasis	8.95e-05	0.00341	CbGpPWpGaD
Formoterol—Rash—Hydrocortisone—psoriasis	8.88e-05	0.000255	CcSEcCtD
Formoterol—Dermatitis—Hydrocortisone—psoriasis	8.87e-05	0.000255	CcSEcCtD
Formoterol—ADRB2—Signaling by GPCR—HCAR2—psoriasis	8.84e-05	0.00337	CbGpPWpGaD
Formoterol—Headache—Hydrocortisone—psoriasis	8.82e-05	0.000253	CcSEcCtD
Formoterol—Dizziness—Triamcinolone—psoriasis	8.77e-05	0.000252	CcSEcCtD
Formoterol—Anaphylactic shock—Methotrexate—psoriasis	8.76e-05	0.000251	CcSEcCtD
Formoterol—Infection—Methotrexate—psoriasis	8.7e-05	0.00025	CcSEcCtD
Formoterol—Feeling abnormal—Prednisone—psoriasis	8.63e-05	0.000248	CcSEcCtD
Formoterol—Asthenia—Dexamethasone—psoriasis	8.63e-05	0.000248	CcSEcCtD
Formoterol—Asthenia—Betamethasone—psoriasis	8.63e-05	0.000248	CcSEcCtD
Formoterol—Nervous system disorder—Methotrexate—psoriasis	8.59e-05	0.000247	CcSEcCtD
Formoterol—Gastrointestinal pain—Prednisone—psoriasis	8.57e-05	0.000246	CcSEcCtD
Formoterol—Nausea—Prednisolone—psoriasis	8.56e-05	0.000246	CcSEcCtD
Formoterol—Pruritus—Dexamethasone—psoriasis	8.51e-05	0.000244	CcSEcCtD
Formoterol—Pruritus—Betamethasone—psoriasis	8.51e-05	0.000244	CcSEcCtD
Formoterol—Skin disorder—Methotrexate—psoriasis	8.5e-05	0.000244	CcSEcCtD
Formoterol—Vomiting—Triamcinolone—psoriasis	8.43e-05	0.000242	CcSEcCtD
Formoterol—Nausea—Hydrocortisone—psoriasis	8.36e-05	0.00024	CcSEcCtD
Formoterol—Rash—Triamcinolone—psoriasis	8.36e-05	0.00024	CcSEcCtD
Formoterol—Dermatitis—Triamcinolone—psoriasis	8.35e-05	0.00024	CcSEcCtD
Formoterol—Urticaria—Prednisone—psoriasis	8.32e-05	0.000239	CcSEcCtD
Formoterol—Headache—Triamcinolone—psoriasis	8.31e-05	0.000239	CcSEcCtD
Formoterol—Abdominal pain—Prednisone—psoriasis	8.28e-05	0.000238	CcSEcCtD
Formoterol—Body temperature increased—Prednisone—psoriasis	8.28e-05	0.000238	CcSEcCtD
Formoterol—Diarrhoea—Betamethasone—psoriasis	8.23e-05	0.000236	CcSEcCtD
Formoterol—Diarrhoea—Dexamethasone—psoriasis	8.23e-05	0.000236	CcSEcCtD
Formoterol—Hypotension—Methotrexate—psoriasis	8.18e-05	0.000235	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Methotrexate—psoriasis	7.98e-05	0.000229	CcSEcCtD
Formoterol—Dizziness—Betamethasone—psoriasis	7.96e-05	0.000228	CcSEcCtD
Formoterol—Dizziness—Dexamethasone—psoriasis	7.96e-05	0.000228	CcSEcCtD
Formoterol—Insomnia—Methotrexate—psoriasis	7.92e-05	0.000227	CcSEcCtD
Formoterol—Nausea—Triamcinolone—psoriasis	7.88e-05	0.000226	CcSEcCtD
Formoterol—Dyspnoea—Methotrexate—psoriasis	7.81e-05	0.000224	CcSEcCtD
Formoterol—Somnolence—Methotrexate—psoriasis	7.78e-05	0.000224	CcSEcCtD
Formoterol—Hypersensitivity—Prednisone—psoriasis	7.72e-05	0.000222	CcSEcCtD
Formoterol—Dyspepsia—Methotrexate—psoriasis	7.71e-05	0.000221	CcSEcCtD
Formoterol—Vomiting—Dexamethasone—psoriasis	7.65e-05	0.00022	CcSEcCtD
Formoterol—Vomiting—Betamethasone—psoriasis	7.65e-05	0.00022	CcSEcCtD
Formoterol—Rash—Dexamethasone—psoriasis	7.59e-05	0.000218	CcSEcCtD
Formoterol—Rash—Betamethasone—psoriasis	7.59e-05	0.000218	CcSEcCtD
Formoterol—Dermatitis—Dexamethasone—psoriasis	7.58e-05	0.000218	CcSEcCtD
Formoterol—Dermatitis—Betamethasone—psoriasis	7.58e-05	0.000218	CcSEcCtD
Formoterol—Gastrointestinal disorder—Methotrexate—psoriasis	7.56e-05	0.000217	CcSEcCtD
Formoterol—Fatigue—Methotrexate—psoriasis	7.55e-05	0.000217	CcSEcCtD
Formoterol—Headache—Betamethasone—psoriasis	7.54e-05	0.000216	CcSEcCtD
Formoterol—Headache—Dexamethasone—psoriasis	7.54e-05	0.000216	CcSEcCtD
Formoterol—Asthenia—Prednisone—psoriasis	7.52e-05	0.000216	CcSEcCtD
Formoterol—Pain—Methotrexate—psoriasis	7.49e-05	0.000215	CcSEcCtD
Formoterol—Pruritus—Prednisone—psoriasis	7.41e-05	0.000213	CcSEcCtD
Formoterol—Feeling abnormal—Methotrexate—psoriasis	7.22e-05	0.000207	CcSEcCtD
Formoterol—Diarrhoea—Prednisone—psoriasis	7.17e-05	0.000206	CcSEcCtD
Formoterol—Gastrointestinal pain—Methotrexate—psoriasis	7.16e-05	0.000206	CcSEcCtD
Formoterol—Nausea—Betamethasone—psoriasis	7.15e-05	0.000205	CcSEcCtD
Formoterol—Nausea—Dexamethasone—psoriasis	7.15e-05	0.000205	CcSEcCtD
Formoterol—Urticaria—Methotrexate—psoriasis	6.96e-05	0.0002	CcSEcCtD
Formoterol—Dizziness—Prednisone—psoriasis	6.93e-05	0.000199	CcSEcCtD
Formoterol—Abdominal pain—Methotrexate—psoriasis	6.92e-05	0.000199	CcSEcCtD
Formoterol—Body temperature increased—Methotrexate—psoriasis	6.92e-05	0.000199	CcSEcCtD
Formoterol—Vomiting—Prednisone—psoriasis	6.66e-05	0.000191	CcSEcCtD
Formoterol—Rash—Prednisone—psoriasis	6.61e-05	0.00019	CcSEcCtD
Formoterol—Dermatitis—Prednisone—psoriasis	6.6e-05	0.00019	CcSEcCtD
Formoterol—Headache—Prednisone—psoriasis	6.56e-05	0.000188	CcSEcCtD
Formoterol—Hypersensitivity—Methotrexate—psoriasis	6.45e-05	0.000185	CcSEcCtD
Formoterol—Asthenia—Methotrexate—psoriasis	6.28e-05	0.00018	CcSEcCtD
Formoterol—Nausea—Prednisone—psoriasis	6.22e-05	0.000179	CcSEcCtD
Formoterol—Pruritus—Methotrexate—psoriasis	6.19e-05	0.000178	CcSEcCtD
Formoterol—Diarrhoea—Methotrexate—psoriasis	5.99e-05	0.000172	CcSEcCtD
Formoterol—CYP2A6—Metabolism—NDUFA5—psoriasis	5.93e-05	0.00226	CbGpPWpGaD
Formoterol—Dizziness—Methotrexate—psoriasis	5.79e-05	0.000166	CcSEcCtD
Formoterol—Vomiting—Methotrexate—psoriasis	5.57e-05	0.00016	CcSEcCtD
Formoterol—Rash—Methotrexate—psoriasis	5.52e-05	0.000159	CcSEcCtD
Formoterol—Dermatitis—Methotrexate—psoriasis	5.52e-05	0.000158	CcSEcCtD
Formoterol—Headache—Methotrexate—psoriasis	5.49e-05	0.000158	CcSEcCtD
Formoterol—ADRB1—Signaling Pathways—HCAR2—psoriasis	5.34e-05	0.00204	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HCAR2—psoriasis	5.22e-05	0.00199	CbGpPWpGaD
Formoterol—Nausea—Methotrexate—psoriasis	5.2e-05	0.000149	CcSEcCtD
Formoterol—ADRB1—GPCR downstream signaling—CCL20—psoriasis	5.17e-05	0.00197	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—CCL20—psoriasis	5.06e-05	0.00193	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CYP2S1—psoriasis	5.05e-05	0.00193	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CCL20—psoriasis	4.7e-05	0.00179	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TAGAP—psoriasis	4.63e-05	0.00177	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CCL20—psoriasis	4.59e-05	0.00175	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TAGAP—psoriasis	4.53e-05	0.00173	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NDUFA5—psoriasis	3.62e-05	0.00138	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.37e-05	0.00129	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NDUFA5—psoriasis	3.33e-05	0.00127	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NDUFA5—psoriasis	3.3e-05	0.00126	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.24e-05	0.00124	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.17e-05	0.00121	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP2S1—psoriasis	3.08e-05	0.00117	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.08e-05	0.00117	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP2S1—psoriasis	2.83e-05	0.00108	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP2S1—psoriasis	2.81e-05	0.00107	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCL20—psoriasis	2.77e-05	0.00106	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCL20—psoriasis	2.71e-05	0.00104	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—CXCL8—psoriasis	2.47e-05	0.000943	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CARM1—psoriasis	2.46e-05	0.00094	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—CXCL8—psoriasis	2.42e-05	0.000922	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.61e-05	0.000615	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SOCS1—psoriasis	1.53e-05	0.000583	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CAT—psoriasis	1.52e-05	0.000578	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CARM1—psoriasis	1.5e-05	0.000573	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SOCS1—psoriasis	1.49e-05	0.00057	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.47e-05	0.000561	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—TYK2—psoriasis	1.46e-05	0.000556	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—TYK2—psoriasis	1.42e-05	0.000544	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.4e-05	0.000536	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—CXCL8—psoriasis	1.4e-05	0.000533	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CARM1—psoriasis	1.38e-05	0.000527	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CARM1—psoriasis	1.37e-05	0.000523	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—CXCL8—psoriasis	1.37e-05	0.000521	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.28e-05	0.000489	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CXCL8—psoriasis	1.27e-05	0.000484	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CXCL8—psoriasis	1.24e-05	0.000473	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—APOE—psoriasis	1.18e-05	0.000449	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—APOE—psoriasis	1.13e-05	0.00043	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—LEP—psoriasis	1.13e-05	0.00043	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—APOE—psoriasis	1.1e-05	0.000421	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—LEP—psoriasis	1.1e-05	0.000421	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NFKBIA—psoriasis	1.05e-05	0.000401	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NFKBIA—psoriasis	1.03e-05	0.000392	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PPARG—psoriasis	1.03e-05	0.000391	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CAT—psoriasis	9.24e-06	0.000353	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TYK2—psoriasis	8.6e-06	0.000328	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CAT—psoriasis	8.5e-06	0.000324	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CAT—psoriasis	8.43e-06	0.000321	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TYK2—psoriasis	8.42e-06	0.000321	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CXCL8—psoriasis	7.49e-06	0.000286	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CXCL8—psoriasis	7.33e-06	0.00028	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—APOE—psoriasis	7.18e-06	0.000274	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL6—psoriasis	7.12e-06	0.000272	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL6—psoriasis	6.97e-06	0.000266	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—JUN—psoriasis	6.96e-06	0.000266	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—JUN—psoriasis	6.81e-06	0.00026	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NFKB1—psoriasis	6.7e-06	0.000256	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—APOE—psoriasis	6.6e-06	0.000252	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NFKB1—psoriasis	6.56e-06	0.00025	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—APOE—psoriasis	6.55e-06	0.00025	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PPARG—psoriasis	6.25e-06	0.000239	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—VEGFA—psoriasis	6.08e-06	0.000232	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—STAT3—psoriasis	6.02e-06	0.00023	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—VEGFA—psoriasis	5.95e-06	0.000227	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—STAT3—psoriasis	5.89e-06	0.000225	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PPARG—psoriasis	5.75e-06	0.000219	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PPARG—psoriasis	5.7e-06	0.000218	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TP53—psoriasis	4.6e-06	0.000175	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TP53—psoriasis	4.5e-06	0.000172	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL6—psoriasis	4.21e-06	0.000161	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL6—psoriasis	4.12e-06	0.000157	CbGpPWpGaD
